Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy (original) (raw)

Accession codes

Accessions

Gene Expression Omnibus

References

  1. Kroemer, G., Galluzzi, L., Kepp, O. & Zitvogel, L. Immunogenic cell death in cancer therapy. Annu. Rev. Immunol. 31, 51–72 (2013).
    CAS PubMed Google Scholar
  2. Tang, D., Kang, R., Coyne, C.B., Zeh, H.J. & Lotze, M.T. PAMPs and DAMPs: signal 0s that spur autophagy and immunity. Immunol. Rev. 249, 158–175 (2012).
    CAS PubMed PubMed Central Google Scholar
  3. Hetz, C., Martinon, F., Rodriguez, D. & Glimcher, L.H. The unfolded protein response: integrating stress signals through the stress sensor IRE1a. Physiol. Rev. 91, 1219–1243 (2011).
    CAS PubMed Google Scholar
  4. Levine, B., Mizushima, N. & Virgin, H.W. Autophagy in immunity and inflammation. Nature 469, 323–335 (2011).
    CAS PubMed PubMed Central Google Scholar
  5. Zitvogel, L., Kepp, O. & Kroemer, G. Decoding cell death signals in inflammation and immunity. Cell 140, 798–804 (2010).
    CAS PubMed Google Scholar
  6. Matzinger, P. The danger model: a renewed sense of self. Science 296, 301–305 (2002).
    CAS PubMed Google Scholar
  7. Zitvogel, L., Kepp, O. & Kroemer, G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat. Rev. Clin. Oncol. 8, 151–160 (2011).
    CAS PubMed Google Scholar
  8. Panaretakis, T. et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J. 28, 578–590 (2009).
    CAS PubMed PubMed Central Google Scholar
  9. Michaud, M. et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 334, 1573–1577 (2011).
    CAS PubMed Google Scholar
  10. Ma, Y. et al. Contribution of IL-17–producing γδ T cells to the efficacy of anticancer chemotherapy. J. Exp. Med. 208, 491–503 (2011).
    CAS PubMed PubMed Central Google Scholar
  11. Ghiringhelli, F. et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors. Nat. Med. 15, 1170–1178 (2009).
    CAS PubMed Google Scholar
  12. Apetoh, L. et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol. Rev. 220, 47–59 (2007).
    CAS PubMed Google Scholar
  13. Senovilla, L. et al. An immunosurveillance mechanism controls cancer cell ploidy. Science 337, 1678–1684 (2012).
    CAS PubMed Google Scholar
  14. González-Navajas, J.M., Lee, J., David, M. & Raz, E. Immunomodulatory functions of type I interferons. Nat. Rev. Immunol. 12, 125–135 (2012).
    PubMed PubMed Central Google Scholar
  15. Ma, Y. et al. CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy. Cancer Res. 74, 436–445 (2014).
    CAS PubMed Google Scholar
  16. Lim, E.S., Wu, L.I., Malik, H.S. & Emerman, M. The function and evolution of the restriction factor Viperin in primates was not driven by lentiviruses. Retrovirology 9, 55 (2012).
    CAS PubMed PubMed Central Google Scholar
  17. Hovanessian, A.G. et al. Identification of 69-kd and 100-kd forms of 2–5A synthetase in interferon-treated human cells by specific monoclonal antibodies. EMBO J. 6, 1273–1280 (1987).
    CAS PubMed PubMed Central Google Scholar
  18. Horisberger, M.A. Interferons, Mx genes, and resistance to influenza virus. Am. J. Respir. Crit. Care Med. 152, S67–S71 (1995).
    CAS PubMed Google Scholar
  19. Yoneyama, M. et al. The RNA helicase RIG-I has an essential function in double-stranded RNA–induced innate antiviral responses. Nat. Immunol. 5, 730–737 (2004).
    CAS PubMed Google Scholar
  20. Tareen, S.U. & Emerman, M. Human Trim5α has additional activities that are uncoupled from retroviral capsid recognition. Virology 409, 113–120 (2011).
    CAS PubMed Google Scholar
  21. Sen, G.C. & Fensterl, V. Crystal structure of IFIT2 (ISG54) predicts functional properties of IFITs. Cell Res. 22, 1407–1409 (2012).
    CAS PubMed PubMed Central Google Scholar
  22. Honda, K. et al. IRF-7 is the master regulator of type-I interferon–dependent immune responses. Nature 434, 772–777 (2005).
    CAS PubMed Google Scholar
  23. Ma, Y. et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 38, 729–741 (2013).
    CAS PubMed Google Scholar
  24. Brahmer, J.R. et al. Safety and activity of anti–PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455–2465 (2012).
    CAS PubMed PubMed Central Google Scholar
  25. Foloppe, J. et al. Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus. Gene Ther. 15, 1361–1371 (2008).
    CAS PubMed Google Scholar
  26. Barbalat, R., Ewald, S.E., Mouchess, M.L. & Barton, G.M. Nucleic acid recognition by the innate immune system. Annu. Rev. Immunol. 29, 185–214 (2011).
    CAS PubMed Google Scholar
  27. Goubau, D., Deddouche, S. & Reis, E.S.C. Cytosolic sensing of viruses. Immunity 38, 855–869 (2013).
    CAS PubMed PubMed Central Google Scholar
  28. Crawford, M.A. et al. Interferon-inducible CXC chemokines directly contribute to host defense against inhalational anthrax in a murine model of infection. PLoS Pathog. 6, e1001199 (2010).
    PubMed PubMed Central Google Scholar
  29. Iwamoto, T. et al. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J. Natl. Cancer Inst. 103, 264–272 (2011).
    CAS PubMed Google Scholar
  30. Tabchy, A. et al. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin. Cancer Res. 16, 5351–5361 (2010).
    CAS PubMed PubMed Central Google Scholar
  31. Hatzis, C. et al. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. J. Am. Med. Assoc. 305, 1873–1881 (2011).
    CAS Google Scholar
  32. Desmedt, C. et al. Multifactorial approach to predicting resistance to anthracyclines. J. Clin. Oncol. 29, 1578–1586 (2011).
    CAS PubMed Google Scholar
  33. Horak, C.E. et al. Biomarker analysis of neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or Paclitaxel in early-stage breast cancer. Clin. Cancer Res. 19, 1587–1595 (2013).
    CAS PubMed Google Scholar
  34. Popovici, V. et al. Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res. 12, R5 (2010).
    PubMed PubMed Central Google Scholar
  35. Allred, D.C., Harvey, J.M., Berardo, M. & Clark, G.M. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod. Pathol. 11, 155–168 (1998).
    CAS PubMed Google Scholar
  36. Arriagada, R. Results of two randomized trials evaluating adjuvant anthracycline-based chemotherapy in 1146 patients with early breast cancer. Acta Oncol. 44, 458–466 (2005).
    CAS PubMed Google Scholar
  37. Spielmann, M. et al. Trastuzumab for patients with axillary-node–positive breast cancer: results of the FNCLCC-PACS 04 trial. J. Clin. Oncol. 27, 6129–6134 (2009).
    CAS PubMed Google Scholar
  38. MacMicking, J.D. Interferon-inducible effector mechanisms in cell-autonomous immunity. Nat. Rev. Immunol. 12, 367–382 (2012).
    CAS PubMed PubMed Central Google Scholar
  39. Alexopoulou, L., Holt, A.C., Medzhitov, R. & Flavell, R.A. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 413, 732–738 (2001).
    CAS PubMed Google Scholar
  40. Tatematsu, M., Nishikawa, F., Seya, T. & Matsumoto, M. Toll-like receptor 3 recognizes incomplete stem structures in single-stranded viral RNA. Nat. Commun. 4, 1833 (2013).
    PubMed Google Scholar
  41. Shatz, M., Menendez, D. & Resnick, M.A. The human TLR innate immune gene family is differentially influenced by DNA stress and p53 status in cancer cells. Cancer Res. 72, 3948–3957 (2012).
    CAS PubMed PubMed Central Google Scholar
  42. Bernard, J.J. et al. Ultraviolet radiation damages self noncoding RNA and is detected by TLR3. Nat. Med. 18, 1286–1290 (2012).
    CAS PubMed Google Scholar
  43. Van, D.N. et al. Innate immune agonist, dsRNA, induces apoptosis in ovarian cancer cells and enhances the potency of cytotoxic chemotherapeutics. FASEB J. 26, 3188–3198 (2012).
    CAS PubMed PubMed Central Google Scholar
  44. Ellermeier, J. et al. Therapeutic efficacy of bifunctional siRNA combining TGF-β1 silencing with RIG-I activation in pancreatic cancer. Cancer Res. 73, 1709–1720 (2013).
    CAS PubMed Google Scholar
  45. Salaun, B. et al. TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer. Cancer Res. 71, 1607–1614 (2011).
    CAS PubMed Google Scholar
  46. Conforti, R. et al. Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. Cancer Res. 70, 490–500 (2010).
    CAS PubMed Google Scholar
  47. Schreiber, R.D., Old, L.J. & Smyth, M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331, 1565–1570 (2011).
    CAS PubMed Google Scholar
  48. Vesely, M.D., Kershaw, M.H., Schreiber, R.D. & Smyth, M.J. Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 29, 235–271 (2011).
    CAS PubMed Google Scholar
  49. Lenci, R.E. et al. Influence of genetic variants in type I interferon genes on melanoma survival and therapy. PLoS ONE 7, e50692 (2012).
    CAS PubMed PubMed Central Google Scholar
  50. Fuertes, M.B. et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells. J. Exp. Med. 208, 2005–2016 (2011).
    CAS PubMed PubMed Central Google Scholar
  51. Diamond, M.S. et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J. Exp. Med. 208, 1989–2003 (2011).
    CAS PubMed PubMed Central Google Scholar
  52. Harlin, H. et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 69, 3077–3085 (2009).
    CAS PubMed Google Scholar
  53. Hong, M. et al. Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control. Cancer Res. 71, 6997–7009 (2011).
    CAS PubMed Google Scholar
  54. Eggermont, A.M. et al. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur. J. Cancer 48, 218–225 (2012).
    CAS PubMed Google Scholar
  55. Ruffell, B. et al. Leukocyte composition of human breast cancer. Proc. Natl. Acad. Sci. USA 109, 2796–2801 (2012).
    CAS PubMed Google Scholar
  56. Gu-Trantien, C. et al. CD4+ follicular helper T cell infiltration predicts breast cancer survival. J. Clin. Invest. 123, 2873–2892 (2013).
    CAS PubMed PubMed Central Google Scholar
  57. Denkert, C. et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol. 28, 105–113 (2010).
    CAS PubMed Google Scholar
  58. Weichselbaum, R.R. et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc. Natl. Acad. Sci. USA 105, 18490–18495 (2008).
    CAS PubMed PubMed Central Google Scholar
  59. Chan, S.R. et al. STAT1-deficient mice spontaneously develop estrogen receptor α–positive luminal mammary carcinomas. Breast Cancer Res. 14, R16 (2012).
    CAS PubMed PubMed Central Google Scholar
  60. Yang, X. et al. Targeting the tumor microenvironment with interferon-β bridges innate and adaptive immune responses. Cancer Cell 25, 37–48 (2014).
    PubMed PubMed Central Google Scholar
  61. Sheehan, K.C. et al. Blocking monoclonal antibodies specific for mouse IFN-α/β receptor subunit 1 (IFNAR-1) from mice immunized by in vivo hydrodynamic transfection. J. Interferon Cytokine Res. 26, 804–819 (2006).
    CAS PubMed Google Scholar
  62. Uppaluri, R. et al. Prolongation of cardiac and islet allograft survival by a blocking hamster anti-mouse CXCR3 monoclonal antibody. Transplantation. 86, 137–147 (2008).
    CAS PubMed PubMed Central Google Scholar
  63. Gresser, I., Tovey, M.G., Maury, C. & Bandu, M.T. Role of interferon in the pathogenesis of virus diseases in mice as demonstrated by the use of anti-interferon serum. II. Studies with herpes simplex, Moloney sarcoma, vesicular stomatitis, Newcastle disease, and influenza viruses. J. Exp. Med. 144, 1316–1323 (1976).
    CAS PubMed Google Scholar
  64. Tovey, M.G., Begon-Lours, J. & Gresser, I. A method for the large scale production of potent interferon preparations. Proc. Soc. Exp. Biol. Med. 146, 809–815 (1974).
    CAS PubMed Google Scholar
  65. Gaj, T., Guo, J., Kato, Y., Sirk, S.J. & Barbas, C.F. III. Targeted gene knockout by direct delivery of zinc-finger nuclease proteins. Nat. Methods 9, 805–807 (2012).
    CAS PubMed PubMed Central Google Scholar
  66. Galluzzi, L. et al. Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ. 16, 1093–1107 (2009).
    CAS PubMed Google Scholar
  67. Galluzzi, L. et al. Prognostic impact of vitamin B6 metabolism in lung cancer. Cell Reports 2, 257–269 (2012).
    CAS PubMed Google Scholar
  68. Kepp, O., Galluzzi, L., Lipinski, M., Yuan, J. & Kroemer, G. Cell death assays for drug discovery. Nat. Rev. Drug Discov. 10, 221–237 (2011).
    CAS PubMed Google Scholar
  69. Criollo, A. et al. Mitochondrial control of cell death induced by hyperosmotic stress. Apoptosis 12, 3–18 (2007).
    CAS PubMed Google Scholar
  70. Schultze, J.L. & Eggle, D. IlluminaGUI: graphical user interface for analyzing gene expression data generated on the Illumina platform. Bioinformatics 23, 1431–1433 (2007).
    CAS PubMed Google Scholar
  71. Antonov, J. et al. Molecular risk assessment of BIG 1–98 participants by expression profiling using RNA from archival tissue. BMC Cancer 10, 37 (2010).
    PubMed PubMed Central Google Scholar
  72. Gong, Y. et al. Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol. 8, 203–211 (2007).
    CAS PubMed Google Scholar

Download references

Acknowledgements

We acknowledge L. Galluzzi for help with preparation of the manuscript. We thank P. Rameau, Y. Lécluse and M. Sanchez for assistance with FACS experiments, G. Schiavoni and G. D'Agostino (Istituto Superiore di Sanità) for recombinant Ifn-α1, our colleagues from the Gustave Roussy Cancer Center and the Istituto Superiore di Sanità animal facilities, P. Gonin, M. Macchia and E. Cardarelli. We acknowledge P. Vielh for his help with immunohistochemical analyses and G. Stoll for his support in statistical analyses. G.K. and L.Z. are supported by the Ligue Nationale contre le Cancer (Equipes labellisées), Site de Recherche Intégrée sur le Cancer (IRIC) Socrates, the ISREC Foundation, Agence Nationale pour la Recherche (ANR AUTOPH, ANR Emergence), the European Commission (ArtForce), a European Research Council Advanced Investigator Grant (to G.K.), the Fondation pour la Recherche Médicale (FRM), the Institut National du Cancer (INCa), the Fondation de France, Cancéropôle Ile-de-France, the Fondation Bettencourt-Schueller, the LabEx Immuno-Oncology and the Paris Alliance of Cancer Research Institutes. A.S. is supported by Ligue Nationale contre le Cancer. D.H. was supported by Fondation Association pour la Recherche sur le Cancer. M.J.S. was supported by a National Health and Medical Research Council (NH&MRC) Australia Fellowship and Program Grant and a grant from the Victorian Cancer Agency. E.P. and L.B. were supported by Associazione Italiana Ricerca contro il Cancro (AIRC) (MFAG_13058). C.P. was supported by the Deutsche Forschungsgemeinschaft (DFG) PF809/1-1. C.E. was supported by Boerhinger Ingelheim. F.A. was supported by Association Vie et Cancer. J.A. was supported by Institut national du Cancer et la Direction Générale de l′Offre de Soins-INSERM 6043.

Author information

Author notes

  1. Antonella Sistigu, Takahiro Yamazaki and Erika Vacchelli: These authors contributed equally to this work.
  2. Fabrice André, Guido Kroemer and Laurence Zitvogel: These authors jointly supervised this work.

Authors and Affiliations

  1. Gustave Roussy Cancer Campus, Villejuif, France
    Antonella Sistigu, Takahiro Yamazaki, Erika Vacchelli, Julien Adam, Aicha Goubar, Elisa E Baracco, Catarina Remédios, Laetitia Fend, Dalil Hannani, Laetitia Aymeric, Yuting Ma, Mireia Niso-Santano, Oliver Kepp, Virginie Quidville, Rosa Conforti, Vichnou Poirier-Colame, Suzette Delaloge, Joanna Cyrta, Marie-Charlotte Dessoliers, Fabrice André, Guido Kroemer & Laurence Zitvogel
  2. INSERM, U1015, Villejuif, France
    Antonella Sistigu, Takahiro Yamazaki, Catarina Remédios, Laetitia Fend, Dalil Hannani, Laetitia Aymeric, Rosa Conforti & Vichnou Poirier-Colame
  3. Université Paris Saclay, Faculté de Médecine, Le Kremlin Bicêtre, France
    Antonella Sistigu, Takahiro Yamazaki, Erika Vacchelli, Elisa E Baracco, Catarina Remédios, Dalil Hannani, Laetitia Aymeric, Yuting Ma, Mireia Niso-Santano, Oliver Kepp, Alexander Eggermont, Fabrice André & Laurence Zitvogel
  4. Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy
    Antonella Sistigu, Filippo Belardelli, Laura Bracci, Valentina La Sorsa, Giovanna Ziccheddu, Paola Sestili, Francesca Urbani & Enrico Proietti
  5. INSERM, U848, Villejuif, France
    Erika Vacchelli, Kariman Chaba, David P Enot, Elisa E Baracco, Yuting Ma, Mireia Niso-Santano, Oliver Kepp & Guido Kroemer
  6. Equipe 11 Labellisée par la Ligue Nationale Contre le Cancer, Centre de Recherche des Cordeliers, Paris, France
    Kariman Chaba & David P Enot
  7. Université Paris Descartes, Sorbonne Paris Cité, Paris, France
    Kariman Chaba, David P Enot & Guido Kroemer
  8. Department of Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif, France
    Julien Adam, Suzette Delaloge, Joanna Cyrta & Fabrice André
  9. Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France
    Julien Adam, Virginie Quidville & Fabrice André
  10. Regina Elena National Cancer Institute, Rome, Italy
    Ilio Vitale
  11. INSERM, U981, Villejuif, France
    Aicha Goubar, Marie-Charlotte Dessoliers & Fabrice André
  12. Transgene S.A., Illkirch-Graffenstaden, France
    Laetitia Fend & Xavier Préville
  13. Laboratory for Genomics and Immunoregulation, Life and Medical Sciences (LIMES), University of Bonn, Bonn, Germany
    Joachim L Schultze
  14. Department of Dermatology, Laboratory of Experimental Dermatology, University Hospital Bonn, Bonn, Germany
    Thomas Tüting
  15. SIB–Swiss Institute of Bioinformatics, Lausanne, Switzerland
    Mauro Delorenzi
  16. National Center of Competence in Research (NCCR) Molecular Oncology, Institut Suisse de Recherche Expérimentale sur le Cancer (ISREC), School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
    Mauro Delorenzi
  17. Departement de Formation et Recherche, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
    Mauro Delorenzi
  18. Department of Pathology, Centre Claudius Regaud, Toulouse, France
    Magali Lacroix-Triki
  19. Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif, France
    Rosa Conforti, Vichnou Poirier-Colame & Laurence Zitvogel
  20. Department of Medical Oncology, Hôpital Pitie Salpetriere, Paris, France
    Rosa Conforti & Jean-Philippe Spano
  21. Yale School of Medicine, New Haven, Connecticut, USA
    Lajos Pusztai
  22. Department of Pathology, Jean Perrin Center, EA 4677 ERTICa, University of Auvergne, Clermont-Ferrand, France
    Frederique Penault-Llorca
  23. Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France
    Sylvain Ladoire & Laurent Arnould
  24. INSERM, CRI-866 Faculty of Medicine, Dijon, France
    Sylvain Ladoire & Laurent Arnould
  25. University of Burgundy, Dijon, France
    Sylvain Ladoire & Laurent Arnould
  26. San Raffaele University and Scientific Institute, Milan, Italy
    Marco E Bianchi
  27. Center for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Mikael Pittet, Camilla Engblom & Christina Pfirschke
  28. Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Mikael Pittet, Camilla Engblom & Christina Pfirschke
  29. CNRS UMR5235, University Montpellier II, Place Eugène Bataillon, Montpellier, France
    Gilles Uzè
  30. Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA
    Robert D Schreiber
  31. Queensland Institute of Medical Research, Herston, Queensland, Australia
    Melvyn T Chow & Mark J Smyth
  32. School of Medicine, The University of Queensland, Herston, Queensland, Australia
    Mark J Smyth
  33. Metabolomics Platform, Gustave Roussy Cancer Campus, Villejuif, France
    Guido Kroemer
  34. Pôle de Biologie, Hôpital Européen Georges Pompidou, Assistance Publique–Hôpitaux de Paris (AP-HP), Paris, France
    Guido Kroemer

Authors

  1. Antonella Sistigu
    You can also search for this author inPubMed Google Scholar
  2. Takahiro Yamazaki
    You can also search for this author inPubMed Google Scholar
  3. Erika Vacchelli
    You can also search for this author inPubMed Google Scholar
  4. Kariman Chaba
    You can also search for this author inPubMed Google Scholar
  5. David P Enot
    You can also search for this author inPubMed Google Scholar
  6. Julien Adam
    You can also search for this author inPubMed Google Scholar
  7. Ilio Vitale
    You can also search for this author inPubMed Google Scholar
  8. Aicha Goubar
    You can also search for this author inPubMed Google Scholar
  9. Elisa E Baracco
    You can also search for this author inPubMed Google Scholar
  10. Catarina Remédios
    You can also search for this author inPubMed Google Scholar
  11. Laetitia Fend
    You can also search for this author inPubMed Google Scholar
  12. Dalil Hannani
    You can also search for this author inPubMed Google Scholar
  13. Laetitia Aymeric
    You can also search for this author inPubMed Google Scholar
  14. Yuting Ma
    You can also search for this author inPubMed Google Scholar
  15. Mireia Niso-Santano
    You can also search for this author inPubMed Google Scholar
  16. Oliver Kepp
    You can also search for this author inPubMed Google Scholar
  17. Joachim L Schultze
    You can also search for this author inPubMed Google Scholar
  18. Thomas Tüting
    You can also search for this author inPubMed Google Scholar
  19. Filippo Belardelli
    You can also search for this author inPubMed Google Scholar
  20. Laura Bracci
    You can also search for this author inPubMed Google Scholar
  21. Valentina La Sorsa
    You can also search for this author inPubMed Google Scholar
  22. Giovanna Ziccheddu
    You can also search for this author inPubMed Google Scholar
  23. Paola Sestili
    You can also search for this author inPubMed Google Scholar
  24. Francesca Urbani
    You can also search for this author inPubMed Google Scholar
  25. Mauro Delorenzi
    You can also search for this author inPubMed Google Scholar
  26. Magali Lacroix-Triki
    You can also search for this author inPubMed Google Scholar
  27. Virginie Quidville
    You can also search for this author inPubMed Google Scholar
  28. Rosa Conforti
    You can also search for this author inPubMed Google Scholar
  29. Jean-Philippe Spano
    You can also search for this author inPubMed Google Scholar
  30. Lajos Pusztai
    You can also search for this author inPubMed Google Scholar
  31. Vichnou Poirier-Colame
    You can also search for this author inPubMed Google Scholar
  32. Suzette Delaloge
    You can also search for this author inPubMed Google Scholar
  33. Frederique Penault-Llorca
    You can also search for this author inPubMed Google Scholar
  34. Sylvain Ladoire
    You can also search for this author inPubMed Google Scholar
  35. Laurent Arnould
    You can also search for this author inPubMed Google Scholar
  36. Joanna Cyrta
    You can also search for this author inPubMed Google Scholar
  37. Marie-Charlotte Dessoliers
    You can also search for this author inPubMed Google Scholar
  38. Alexander Eggermont
    You can also search for this author inPubMed Google Scholar
  39. Marco E Bianchi
    You can also search for this author inPubMed Google Scholar
  40. Mikael Pittet
    You can also search for this author inPubMed Google Scholar
  41. Camilla Engblom
    You can also search for this author inPubMed Google Scholar
  42. Christina Pfirschke
    You can also search for this author inPubMed Google Scholar
  43. Xavier Préville
    You can also search for this author inPubMed Google Scholar
  44. Gilles Uzè
    You can also search for this author inPubMed Google Scholar
  45. Robert D Schreiber
    You can also search for this author inPubMed Google Scholar
  46. Melvyn T Chow
    You can also search for this author inPubMed Google Scholar
  47. Mark J Smyth
    You can also search for this author inPubMed Google Scholar
  48. Enrico Proietti
    You can also search for this author inPubMed Google Scholar
  49. Fabrice André
    You can also search for this author inPubMed Google Scholar
  50. Guido Kroemer
    You can also search for this author inPubMed Google Scholar
  51. Laurence Zitvogel
    You can also search for this author inPubMed Google Scholar

Contributions

A.S., T.Y., E.V., K.C., I.V., E.E.B., C.R., L.F., D.H., L. Aymeric, Y.M., M.N.-S., O.K., J.L.S., V.L.S., G.Z., P.S., F.U., M.P., C.E., C.P., M.J.S. and M.T.C. performed experiments. M.D., V.Q., R.C., J.-P.S., L.P., S.D., A.E. and F.A. enrolled patients in clinical trials. F.B., L.B. and E.P. directed part of A.S.'s experiments and supported the fees of the animal work. F.B., T.T., M.E.B., G.U. and R.D.S. provided reagents. L.Z. daily directed the two first authors and conceived the study. L.Z., F.A. and G.K. wrote the paper. V.P.-C. processed the TMAs and performed immunostaining of the biopsies and TMAs. A.G. and D.P.E. performed statistical analyses. J.A., S.L., L. Arnould, J.C., M.-C.D., F.P.-L. and M.L.-T. were the pathologists who interpreted the MX1 and TLR3 staining. X.P. and L.F. performed the experiments with transgenic oncolytic viruses.

Corresponding authors

Correspondence toGuido Kroemer or Laurence Zitvogel.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Rights and permissions

About this article

Cite this article

Sistigu, A., Yamazaki, T., Vacchelli, E. et al. Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy.Nat Med 20, 1301–1309 (2014). https://doi.org/10.1038/nm.3708

Download citation